ANI Pharmaceuticals Inc. (ANIP)
NASDAQ: ANIPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ANIP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.65B
- P/E (TTM)
- 15.57
- Forward P/E
- 7.08
- EPS (TTM)
- $4.62
- Dividend yield
- None
- 52-week range
- 69.58 – 97.00
- Day range
- 71.57 – 72.74
- Volume / Avg
- 437.60K / 371.52K
- Beta
- —
- Shares outstanding
- 22.96M
- Next earnings
- Nov 6, 2026
52-week range
ANIP stock today
ANI Pharmaceuticals (ANIP) closed at $71.93 on Oct 7, up 0.57% (+$0.41), versus the S&P 500's 0.22% decline. At this level, ANIP sits near the bottom of its 52-week range of $69.58 to $97.00: 25.8% below the high, set on Oct 24, 2025 and 3.4% above the low. ANIP is down 8.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 21.5%.
ANI Pharmaceuticals trades at 15.6x its trailing twelve-month earnings per share of $4.62. Its forward P/E of 7.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. ANI Pharmaceuticals's next earnings report is expected on Nov 6, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About ANI Pharmaceuticals
Company profileANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Nikhil Lalwani
- Headquarters
- Baudette, MN
- Employees
- 970
- Website
- anipharmaceuticals.com
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$105.78+47.06%
- Strong buy 3
- Buy 4
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 6, 2026
- EPS estimate
- $1.80
ANI Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CMPSCOMPASS Pathways Plc American Depository Shares | 11.69 | +1.12% | $1.62B | vs ANIP |
| BRVEBraveheart Bio Inc. | 18.58 | -6.11% | $1.67B | vs ANIP |
| QUREuniQure N.V. | 23.14 | +0.35% | $1.61B | vs ANIP |
| SEPNSepterna Inc. | 36.00 | +0.93% | $1.68B | vs ANIP |
| OCULOcular Therapeutix Inc. | 7.23 | -1.50% | $1.59B | vs ANIP |
| NUVBNuvation Bio Inc. Class A | 4.86 | -0.41% | $1.71B | vs ANIP |
| GENBGenerate Biomedicines Inc. | 13.57 | -1.67% | $1.74B | vs ANIP |
| BHVNBiohaven Ltd. | 11.88 | -1.66% | $1.79B | vs ANIP |
Indexes, lists and sector
ANI Pharmaceuticals stock FAQ
What is ANI Pharmaceuticals's stock price today?
ANIP last traded at $71.93 as of Oct 7, 4:00 PM EDT, up 0.57% on the day. Prices are delayed at least 15 minutes.
Does ANI Pharmaceuticals pay a dividend?
No. ANI Pharmaceuticals does not currently pay a regular cash dividend.
When is ANI Pharmaceuticals's next earnings date?
ANI Pharmaceuticals is expected to report earnings on Friday, November 6, 2026. Analysts expect EPS of $1.80.
What is ANIP's P/E ratio?
ANIP trades at a trailing P/E ratio of 15.57 and a forward P/E of 7.08.
Who is ANI Pharmaceuticals's CEO?
Mr. Nikhil Lalwani is the chief executive officer of ANI Pharmaceuticals Inc., which has about 970 employees.
Has ANIP ever split its stock?
Yes. The most recent ANIP stock split was a 1-for-6 split on Jul 18, 2013, one of 3 splits on record.
What is the ANIP 52-week high?
The 52-week high for ANIP is $97.00 and the 52-week low is $69.58. The stock is currently 25.8% below its high.